Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1864-1869

  Rajpar, S ^a   Massard, C ^a   Laplanche, A ^a   Tournay, E ^a   Gross Goupil, M ^a   Loriot, Y ^a   di Palma, M ^a   Bossi, A ^a   Escudier, B ^a   Chauchereau, A ^a   Fizazi, K ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bone metastasis; Prostate cancer; uNTx; Zoledronic acid

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE METASTASIS; CANCER PATIENT; CANCER RESISTANCE; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIAGNOSTIC VALUE; FUNCTIONAL STATUS; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SCREENING; SURVIVAL TIME; TREATMENT DURATION;

EID: 77954243551     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq037     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59(4): 225-249.
2. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23(32): 8253-8261.
3. Horwich A. Prostate cancer management. Ann Oncol 2004; 15 (Suppl 4): iv307-v312.
4. Loberg RD, Logothetis CJ, Keller ET et al. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005; 23(32): 8232-8241.
5. Tannock IF, de Wit R, Berry WR et al. TAX 327 investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502-1512.
6. Saad F, Gleason DM, Murray R et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94(19): 1458-1468.
7. Fizazi K, Le Maitre A, Hudes G et al. Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007; 8(11): 994-1000.
8. Oudard S, Banu E, Medioni J, Scotte F. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int 2009; 103(12): 1641-1646.
9. Guise TA, Mohammad KS, Clines G et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006; 12: 6213s-6216s.
10. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-6249s.
11. Fizazi K, Yang J, Peleg S et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003; 9(7): 2587-2597.
12. Roodman GD. Mechanism of bone metastasis. N Engl J Med 2004; 350(16): 1655-1664.
13. Cook RJ, Coleman R, Brown J et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006; 12(11 Pt 1): 3361-3367.
14. Brown JE, Cook RJ, Major P et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97(1): 59-69.
15. Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23(22): 4925-4935.
16. Lipton A, Cook R, Saad F et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113(1): 193-201.
17. Fizazi K, Lipton A, Mariette X et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27(10): 1564-1571.
18. Oades GM, Coxon J, Colston KW. The potential role of bisphosphonates in prostate cancer. Prostate Cancer Prostatic Dis 2002; 5(4): 264-272.
19. Rosen LS, Gordon DH, Dugan W Jr et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100(1): 36-43.
20. Saad F, Gleason DM, Murray R et al. Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96(11): 879-882.
21. Small EJ, Smith MR, Seaman JJ et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21(23): 4277-4284.
22. Dearnaley DP, Sydes MR, Mason MD et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003; 95(17): 1300-1311.
23. Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 2008; 75(10): 739-750.
24. Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 2002; 94(10): 2521-2533.
25. Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20(19): 3972-3982.
26. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer [erratum appears in: J Clin Oncol 2004; 22 (16): 3434]. J Clin Oncol 2003; 21 (7): 1232-1237.
27. Halabi S, Vogelzang NJ, Kornblith AB et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008; 26(15): 2544-2549.
28. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer [erratum appears in: J Clin Oncol 2008; 26 (5): 820]. J Clin Oncol 2007; 25 (25): 3965-3970.
29. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000; 88 (12 Suppl): 2892-2898.
30. Yu EY, Wilding G, Posadas E et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15(23): 7421-7428.
31. James ND, Caty A, Borre M et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55(5): 1112-1123.
32. Fizazi K, Miller K. Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer. BJU Int 2009; 104(10): 1423-1425.
33. Fizazi K, Beuzeboc P, Lumbroso J et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009; 27(15): 2429-2435.
34. Tu SM, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial [erratum appears in: Lancet 2001; 357 (9263): 1210]. Lancet 2001; 357 (9253): 336-341.